BDTX vs. URGN, TLRY, TNGX, STOK, PRME, DNTH, PHAT, UPB, XNCR, and MNMD
Should you be buying Black Diamond Therapeutics stock or one of its competitors? The main competitors of Black Diamond Therapeutics include Urogen Pharma (URGN), Tilray Brands (TLRY), Tango Therapeutics (TNGX), Stoke Therapeutics (STOK), Prime Medicine (PRME), Dianthus Therapeutics (DNTH), Phathom Pharmaceuticals (PHAT), Upstream Bio (UPB), Xencor (XNCR), and Mind Medicine (MindMed) (MNMD). These companies are all part of the "pharmaceutical products" industry.
Black Diamond Therapeutics vs. Its Competitors
Urogen Pharma (NASDAQ:URGN) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.
Urogen Pharma currently has a consensus target price of $32.86, indicating a potential upside of 73.81%. Black Diamond Therapeutics has a consensus target price of $12.80, indicating a potential upside of 330.25%. Given Black Diamond Therapeutics' higher probable upside, analysts clearly believe Black Diamond Therapeutics is more favorable than Urogen Pharma.
91.3% of Urogen Pharma shares are owned by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 5.1% of Urogen Pharma shares are owned by insiders. Comparatively, 6.0% of Black Diamond Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Urogen Pharma had 9 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 10 mentions for Urogen Pharma and 1 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.91 beat Urogen Pharma's score of 0.64 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.
Black Diamond Therapeutics has a net margin of 0.00% compared to Urogen Pharma's net margin of -150.68%. Black Diamond Therapeutics' return on equity of 4.70% beat Urogen Pharma's return on equity.
Black Diamond Therapeutics has lower revenue, but higher earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.
Urogen Pharma has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, Black Diamond Therapeutics has a beta of 2.71, suggesting that its share price is 171% more volatile than the S&P 500.
Summary
Black Diamond Therapeutics beats Urogen Pharma on 11 of the 15 factors compared between the two stocks.
Get Black Diamond Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BDTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BDTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Black Diamond Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:BDTX) was last updated on 7/25/2025 by MarketBeat.com Staff
